New Jersey Hematology Oncology Associates | Brick Office
Status and phase
Conditions
Treatments
About
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for All Participants:
Inclusion Criteria for Participants with Early-stage NSCLC:
Inclusion Criteria for Participants with Stage IV NSCLC:
Exclusion Criteria for All Participants:
Exclusion Criteria for Participants with Stage IV NSCLC:
Primary purpose
Allocation
Interventional model
Masking
176 participants in 2 patient groups
Loading...
Central trial contact
Reference Study ID Number: MO43576 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal